Opus Genetics, Inc. Earnings Per Share (Basic)
Opus Genetics, Inc. (IRD) reported Earnings Per Share (Basic) of -$0.08 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Opus Genetics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.08.
- Opus Genetics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.75.
- Opus Genetics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.21.
- Opus Genetics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.25.
- Opus Genetics, Inc. earnings per share, basic for fiscal 2025 was -$0.80.
- Opus Genetics, Inc. earnings per share, basic for fiscal 2024 was -$2.15.
- Opus Genetics, Inc. earnings per share, basic for fiscal 2023 was -$0.46, a 151.11% decline from fiscal 2022.
- Opus Genetics, Inc. earnings per share, basic for fiscal 2022 was $0.90.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.08 10-Q · filed 2026-08-06 | -$0.81 10-Q · filed 2026-08-06 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.29 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.75 10-Q · filed 2026-05-12 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.25 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.80 10-K · filed 2026-03-12 |
| 2025-09-30 | -$0.25 10-Q · filed 2025-11-12 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.59 10-Q · filed 2025-11-12 | -$1.38 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.12 10-Q · filed 2026-08-06 | -$0.32 10-Q · filed 2026-08-06 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.24 10-Q · filed 2026-05-12 | -$1.35 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.69 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.02 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.51 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$2.15 10-K · filed 2026-03-12 |
| 2024-09-30 | -$0.29 10-Q · filed 2025-11-12 | -$0.59 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$0.88 10-Q · filed 2025-11-12 | -$1.09 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$0.30 10-Q · filed 2025-08-13 | -$0.59 10-Q · filed 2025-08-13 | -$0.80 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$0.60 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-03-31 | -$0.29 10-Q · filed 2025-05-15 | -$0.50 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$0.28 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$0.50 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2023-12-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2025-03-31 | $0.03 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.19 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.46 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.26 10-Q · filed 2024-11-12 | $0.03 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.25 10-Q · filed 2024-11-12 | $1.37 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-06-30 | -$0.24 10-Q · filed 2024-08-13 | -$0.51 10-Q · filed 2024-08-13 | $1.11 derived: net income ÷ weighted average shares · filed 2024-11-12 | $0.90 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-03-31 | -$0.28 10-Q · filed 2024-05-10 | $1.35 derived: net income ÷ weighted average shares · filed 2024-11-12 | $1.14 derived: net income ÷ weighted average shares · filed 2024-11-12 | $0.91 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2022-12-31 | $1.63 derived: net income ÷ weighted average shares · filed 2024-03-08 | $1.42 derived: net income ÷ weighted average shares · filed 2024-03-08 | $1.21 derived: net income ÷ weighted average shares · filed 2024-03-08 | $0.90 10-K · filed 2024-03-08 |
| 2022-09-30 | -$0.22 10-Q · filed 2023-11-13 | -$0.47 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.82 10-Q · filed 2023-11-13 | -$1.17 derived: net income ÷ weighted average shares · filed 2023-11-13 |
| 2022-06-30 | -$0.25 10-Q · filed 2023-08-11 | -$0.60 10-Q · filed 2023-08-11 | -$0.95 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.21 derived: net income ÷ weighted average shares · filed 2023-11-13 |
| 2022-03-31 | -$0.35 10-Q · filed 2023-05-15 | -$0.70 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.96 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.44 derived: net income ÷ weighted average shares · filed 2023-11-13 |
| 2021-12-31 | -$0.35 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$0.61 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$1.10 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$3.82 10-K · filed 2023-03-30 |
| 2021-09-30 | -$0.25 10-Q · filed 2022-11-04 | -$0.74 derived: net income ÷ weighted average shares · filed 2022-11-04 | -$3.64 10-Q · filed 2022-11-04 | -$5.63 derived: net income ÷ weighted average shares · filed 2022-11-04 |
| 2021-06-30 | -$0.52 10-Q · filed 2022-08-12 | -$3.76 10-Q · filed 2022-08-12 | -$6.05 derived: net income ÷ weighted average shares · filed 2022-11-04 | -$7.37 derived: net income ÷ weighted average shares · filed 2022-11-04 |
| 2021-03-31 | -$3.57 10-Q · filed 2022-05-13 | -$6.23 derived: net income ÷ weighted average shares · filed 2022-11-04 | -$7.94 derived: net income ÷ weighted average shares · filed 2022-11-04 | -$9.31 derived: net income ÷ weighted average shares · filed 2022-11-04 |
| 2020-12-31 | -$2.46 derived: net income ÷ weighted average shares · filed 2022-03-24 | -$3.51 derived: net income ÷ weighted average shares · filed 2022-03-24 | -$4.28 derived: net income ÷ weighted average shares · filed 2022-03-24 | -$5.28 10-K · filed 2022-03-24 |
| 2020-09-30 | -$0.33 10-Q · filed 2021-11-12 | -$0.76 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$1.61 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$0.43 10-Q · filed 2021-08-12 | -$1.29 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$0.87 10-Q · filed 2021-05-07 | |||
| 2018-06-30 | -$0.12 10-Q · filed 2018-08-03 | -$0.19 10-Q · filed 2018-08-03 | ||
| 2017-12-31 | -$0.12 10-K · filed 2019-03-07 | |||
| 2017-09-30 | -$0.04 10-K · filed 2019-03-07 | |||
| 2017-06-30 | $0.04 10-K · filed 2019-03-07 | -$0.83 10-Q · filed 2018-08-03 | ||
| 2017-03-31 | -$0.91 10-K · filed 2019-03-07 | |||
| 2016-06-30 | -$0.08 10-Q · filed 2017-08-04 | -$0.28 10-Q · filed 2017-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |